Cardio-metabolic risks of obesity
Authors:
MUDr. Fábryová Ľubomíra, PhD.
Authors‘ workplace:
MetabolKLINIK s. r. o., Ambulancia pre diabetológiu, poruchy látkovej premeny a výživy, Špecializovaná lipidologická ambulancia, Bratislava
Published in:
Forum Diab 2015; 4(1): 67-74
Category:
Topic
Overview
Obesity is a progressive chronic disease characterized by accumulation of fat and association of many organ-specific metabolic and cardiovascular complications which affect the quality of life and its expectancy in obese subject. Cardio-metabolic complications of obesity are involved in denomination of metabolic syndrome characterized by insulin resistance, visceral obesity, systemic subclinical inflammation, disorders of coagulation and fibrinolysis, and currently, also by ectopic fat tissue. Different stages of impaired glucose tolerance, atherogenic dyslipidaemia, hypertension, disorders of coagulation and fibrinolysis are beyond metabolic syndrome in clinical practice. Obesity and previously mentioned clinical states impact the increase of cardiovascular disease (ischemic heart disease, myocardial infarction). Recent knowledge allows us to intervenient against the increase of cardiovascular diseases with prevention and complex management of obesity and cardiovascular risk factors
Key words:
atherogenic dyslipidaemia – cardio-metabolic diseases – diabetes mellitus – obesity
Sources
1. Aronne LJ, Nelinson DS, Lillo JL et al. Obesity as a disease state: new paradigm for diagnosis and treatment. Clin Cornerstone 2009; 9(4): 9–29.
2. Willett WC, Manson JE, Stampfer MJ et al. Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range. JAMA 1995; 273(6): 461–465.
3. Shaper AG, Wannamethee SG, Walker M. Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. BMJ 1997; 314(7090): 1311–1317.
4. Tokunaga K, Matsuzawa Y, Kotani K et al. Ideal body weight estimated from the body mass index with the lowest morbidity. Int J Obes 1991; 15(1): 1–5.
5. Jousilahti P, Tuomilehto J, Vartiainen E et al. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996; 93(7): 1372–1379.
6. Fábryová Ľ. Kardiometabolické riziká obezity. In: Krahulec B, Fábryová Ľ, Holéczy P et al (eds). Klinická obezitológia. Facta Medica; Brno 2013: 166–177. IBSN 978–80–904731–7-1.
7. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640–1645.
8. Fisman EZ, Tenenbaum A. The metabolic syndrome entanglement: cutting the Gordian knot. Cardiol J 2013; 21(1) :1–5 Dostupné z DOI: <http://dx.doi.org/10.5603/CJ.a2013.0054>.
9. Blüher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab 2013; 27(2):163–177.
10. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93(1): 359–404.
11. Shimabukuro M, Kozuka C, Taira S et al. Ectopic fat deposition and global cardiometabolic risk: New paradigm in cardiovascular medicine. J Med Invest 2013; 60(1–2): 1–14.
12. Boden G, Salehi S. Why does obesity increase the risk for cardiovascular disease? Curr Pharm Des 2013; 19(32): 5678–5683.
13. Persic V. Obesity in the cardiovascular continuum. Curr Clin Pharmacol 2013; 8(2): 159–163.
14. Phillips CM, Tierney AC, Perez-Martinez P et al. Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype. Obesity (Silver Spring) 2013; 21(1): E154-E161.
15. Pedersen SD. Metabolic complications of obesity. Best Pract Res Clin Endocrinol Metab 2013, 27(2): 179–193.
16. Dukát A, Fábryová Ľ. Možné prítupy na zníženie reziduálneho kardiovaskulárneho rizika u pacientov s diabetes mellitus 2. typu. Cardiol 2010; 19(6): 474–480.
17. Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013; 5(4): 1218–1240.
18. Varbo A, Benn M, Tybjærg-Hansen A et al. Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease. J Am Coll Cardiol 2013; 61(4): 427–436.
19. Toth PP. Insulin resistance, small LDL particles, and risk for atherosclerotic disease. Curr Vasc Pharmacol 2014; 12(4):653–657.
20. Catapano AL, Reiner Z, de Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(Suppl 1): 1–44.
21. Chapman MJ, Ginsberg HN, Amarenco P et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32(11): 1345–1361.
22. Fábryová Ľ. Kombinačná hypolipidemická liečba v súčasnej klinickej praxi. Via pract 2014; 11(6): 201–206.
23. Cabral NAL, Ribeiro VS, França AKT et al. Hypertriglyceridemic waist and cardiometabolic risk in hypertensive women. Rev Assoc Med Bras 2012; 58(5): 568–573.
24. Dorresteijn JAN, Visseren FLJ, Spiering W. Mechanisms linking obesity to hypertension. Obes Rev 2012; 13(1): 17–26.
25. Dulloo AG, Montani JP. Body composition, inflammation and thermogenesis in pathways to obesity and the metabolic syndrome: an overview. Obes Rev 2012; 13(Suppl 2): 1–5.
26. Greevenbroek MM, Schalkwijk CG, Stehouwer CDA. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med 2013; 71(4): 174–187.
27. Santilli F, Vazzana N, Liani R et al. Platelet activation in obesity and metabolic syndrome. Obes Rev 2012; 13(1): 27–42.
28. Targher D, Bertolini L, Poli F et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54(12): 3541–3546.
29. Szczepaniak LS, Victor RG, Orci L et al. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res 2007; 101(8): 759–767.
30. Takaoka M, SuzukiH, Shioda S et al. Endovascular injury induded rapid phenotypic changes in perivascular adipose tissue. Artherioscler Thromb Vasc Biol 2010; 30(8): 1576–1582.
31. Ding J, Hsu FC, Harris TB et al. The association of pericardial fat with incidence coronary heart disease. The Multietnic Study of Atherosclerosis (MESA). Am J Clin Nutr 2009; 90(3): 499–504.
32. Tsigos C, Hainer V, Basdevant A et al. Obesity Management Task Force Európskej obezitologickej spoločnosti (European Association for the Study of Obesity). Liečba obezity u dospelých. Európske odporúčania pre klinickú prax. Diabetes a obezita 2009; 9(17): 10–20.
33. Eckel RH, Jakicic JM, Ard JD et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B):2960–2984.
34. Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. Circulation 2014; 129(25 Suppl 2): S102-S138.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2015 Issue 1
Most read in this issue
- The clinical diagnosis of stable coronary artery disease
- Importance of ambulatory blood pressure monitoring and ambulatory ECG monitoring in patients with coronary heart disease
- Coronary artery disease and women
- Diabetes mellitus and arrhythmias